logo.jpg
Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting
November 12, 2020 01:00 ET | Kiadis Pharma N.V.
Data presented support the potential of combining oncolytic virotherapy along with PM21-NK cell adoptive therapy against lung cancer Amsterdam, The Netherlands, November 12, 2020 – Kiadis Pharma N.V....
logo.jpg
Sanofi offers to acquire Kiadis for €308 million
November 02, 2020 01:00 ET | Kiadis Pharma N.V.
This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of...
logo.jpg
Kiadis announces presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting
October 26, 2020 02:00 ET | Kiadis Pharma N.V.
Amsterdam, The Netherlands, October 26, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
logo.jpg
Kiadis announces the placement of €5 million convertible bonds with Kreos
October 01, 2020 01:00 ET | Kiadis Pharma N.V.
9% secured convertible bonds replace €5 million in Kreos debtConversion price €2 per share Remaining Kreos debt facilities reduced to €1.6 million   Amsterdam, The Netherlands, October 1, 2020 –...
logo.jpg
Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs
September 30, 2020 01:00 ET | Kiadis Pharma N.V.
K-NK002 (HSCT): IND approved to enter Phase 2 development K-NK003 (AML R/R): IND approved and multiple patients enrolled for Phase 1 investigator initiated trial for treatment of relapsed/refractory...
logo.jpg
Kiadis and Gulf Coast Regional Blood Center announce collaboration to provide universal donor material for K-NK cell therapy programs
September 28, 2020 01:00 ET | Kiadis Pharma N.V.
Collaboration marks first contractual partnership with supplier of universal donor material Amsterdam, The Netherlands, September 28, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company")...
logo.jpg
Kiadis receives $9.5 million from the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program to fund Kiadis K-NK cell COVID-19 therapy
September 15, 2020 01:00 ET | Kiadis Pharma N.V.
Funding for COVID-19 research and development program (K-NK-ID101), to investigate the potential to establish it as a universal countermeasure to fight COVID-19 and future pandemicsFunding obtained...
logo.jpg
Kiadis announces U.S. FDA approval of the Abigail Wexner Research Institute at Nationwide Children’s Hospital’s IND for a COVID-19 clinical trial with off-the-shelf K-NK cells using Kiadis’ proprietary platforms
September 14, 2020 01:00 ET | Kiadis Pharma N.V.
Amsterdam, The Netherlands, September 14, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
logo.jpg
Kiadis announces investor events for September 2020
September 03, 2020 01:00 ET | Kiadis Pharma N.V.
                                            Company announces Notice of Results for the six months ended June 30, 2020 Amsterdam, The Netherlands, September 3, 2020 – Kiadis Pharma N.V. (“Kiadis” or...
logo.jpg
Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)
August 29, 2020 06:30 ET | Kiadis Pharma N.V.
New data will be presented in an e-poster today at the Virtual Edition of the 46th EBMT Annual Meeting Amsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)...